CompletedPhase 2NCT00553644
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Studying Mantle cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Vicki MorrisonAlliance for Clinical Trials in Oncology
- Intervention
- Bortezomib(drug)
- Enrollment
- 53 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2007 – 2014
Study locations (30)
- Kaiser Permanente-Anaheim, Anaheim, California, United States
- Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States
- Kaiser Permanente-Bellflower, Bellflower, California, United States
- Kaiser Permanente-Fontana, Fontana, California, United States
- Kaiser Permanente - Harbor City, Harbor City, California, United States
- Kaiser Permanente-Irvine, Irvine, California, United States
- Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
- Kaiser Permanente-Cadillac, Los Angeles, California, United States
- Kaiser Permanente - Panorama City, Panorama City, California, United States
- Kaiser Permanente-Riverside, Riverside, California, United States
- Kaiser Permanente-San Diego Mission, San Diego, California, United States
- Kaiser Permanente-San Diego Zion, San Diego, California, United States
- Kaiser Permanente-San Marcos, San Marcos, California, United States
- Kaiser Permanente-Woodland Hills, Woodland Hills, California, United States
- Hartford Hospital, Hartford, Connecticut, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00553644 on ClinicalTrials.govOther trials for Mantle cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06675123Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07377578A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.
- RECRUITINGPHASE2NCT07272499Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRuijin Hospital
- RECRUITINGPHASE2NCT07029737A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in SpainAstraZeneca
- RECRUITINGPHASE2NCT07082686A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)Beijing InnoCare Pharma Tech Co., Ltd.
- RECRUITINGNANCT07257510Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell LymphomaPeking University Third Hospital
- RECRUITINGPHASE2NCT07199296Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL TreatmentRuijin Hospital
- RECRUITINGPHASE2NCT06846489Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell LymphomaSun Yat-sen University